Kymera Therapeutics (KYMR) Enterprise Value (2020 - 2026)

Kymera Therapeutics (KYMR) has reported Enterprise Value for 8 consecutive years, with -$650.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 40.54% year-over-year to -$650.9 million; the TTM figure through Mar 2026 stood at -$650.9 million (down 40.54% YoY), while the FY2025 annual figure was -$848.3 million, down 73.56% from the prior year.
• Enterprise Value grew to -$650.9 million in Q1 2026 per KYMR's latest filing, from -$848.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$33.7 million in Q1 2022 and bottomed at -$848.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$452.9 million across 5 years, with a median of -$481.9 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 89.89% — and 2023, when it plunged 1076.52%.
• Kymera Therapeutics' Enterprise Value stood at -$407.2 million in 2022, then advanced by 7.93% to -$374.9 million in 2023, then slumped by 30.37% to -$488.7 million in 2024, then plunged by 73.56% to -$848.3 million in 2025, then increased by 23.26% to -$650.9 million in 2026.
• Business Quant data shows KYMR's Enterprise Value at -$650.9 million in Q1 2026, -$848.3 million in Q4 2025, and -$505.7 million in Q3 2025.